The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | The potential of CAR-T therapy targeting mutant CALR in myelofibrosis & essential thrombocythemia
Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, discusses the potential of CAR-T therapy targeting mutant calreticulin (CALR) in patients with myeloproliferative neoplasms (MPNs) such as myelofibrosis (MF) and essential thrombocythemia (ET). Prof. Rinaldi comments on his concern for potential side effects but highlights the curative potential of this therapy, especially for MF. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
